drugset / Trial / NCT02343094
Phenylbutyrate in Proteinuric Nephropathies
Phase 2/3
Completed
26 enrolled
Assistance Publique - Hôpitaux de Paris
URC-CIC Paris Descartes Necker Cochin · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether sodium phenylbutyrate can reduce Lcn2 urinary expression in proteinuric patients.
Timeline
- Start
- 2015-02
- Primary completion
- 2015-12
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sodium Phenylbutyrate | Small molecule | 7.5 g | — |
| Subject | Sodium Phenylbutyrate | Small molecule | 15 g | — |